首页 | 本学科首页   官方微博 | 高级检索  
检索        

吉西他滨联合顺铂治疗晚期非小细胞肺癌46例报道
引用本文:陈雅敏,刘基巍,赵翌.吉西他滨联合顺铂治疗晚期非小细胞肺癌46例报道[J].癌症进展,2004,2(4):285-287.
作者姓名:陈雅敏  刘基巍  赵翌
作者单位:大连医科大学附属第一医院,大连,116011;大连医科大学附属第一医院,大连,116011;大连医科大学附属第一医院,大连,116011
摘    要:目的观察吉西他滨联合顺铂治疗晚期非小细胞肺癌临床疗效及不良反应.方法46例患者采用吉西他滨1g/m2,d1,8,15及顺铂90mg/m2分两天(d 2,3)化疗.28天为1周期,3周期评价疗效.结果46例可评价疗效和不良反应.初治病例RR 53.8%;复治病例35%.主要不良反应为骨髓抑制.结论吉西他滨联合顺铂治疗晚期非小细胞肺癌有效率较高,不良反应可以耐受.

关 键 词:非小细胞肺癌  吉西他滨  顺铂  联合化疗

Clinical observation of gemcitabine plus cisplatine in treatment advanced of non-small cell lung cancer
Chen Yamin,Liu Jiwei Zhao Yi.Clinical observation of gemcitabine plus cisplatine in treatment advanced of non-small cell lung cancer[J].Oncology Progress,2004,2(4):285-287.
Authors:Chen Yamin  Liu Jiwei Zhao Yi
Institution:Chen Yamin Liu Jiwei Zhao Yi Department of Oncology,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,China
Abstract:Objective To evaluate the curative effect and toxicity of gemcitabine combined with cisplatine in treatment advance of non-small-cell lung cancer.Methods 46 cases were treated with gemcitabine 1g/m 2 iv d1,8,15,and cisplatine 90mg/m 2 iv d 2,3,repeated every 4 weeks and the clinical response was assesed after three cycles.Results It shows that effective rate of primary treatment was 53.8%,effective rate of re treatment was 35.0%.The principal toxicity was inhibition of bone marrow.Conclusion Gemcitabine combined with cisplatine shows a better theraputic effect in treatment of advanced non-small cell lung cancer,and toxic side-effect are tolerant.
Keywords:non-small cell lung cancer    gemcitabine    cisplatine    combined chemotherapy
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号